Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 455 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Clinical High-Risk Clear all
Completed No phase listed Observational

Study to Evaluate the Human Infection of the Lower Respiratory Tract in Children at High Risk

NCT00192439
View directory record Official record
Conditions
Severe Respiratory Disease
Interventions
High Risk Respiratory Disease
Behavioral
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Day to 24 Months
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
16
States / cities
Long Beach, California • Denver, Colorado • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Oct 23, 2026, 1:46 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

NCT06667700
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
Molnupiravir, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
3,082 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
71
States / cities
Cullman, Alabama • Paradise Valley, Arizona • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 1:46 PM EDT
Completed Phase 3 Interventional

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

NCT00887536
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, docetaxel, doxorubicin, cyclophosphamide, pegfilgrastim
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years to 70 Years · Female only
Enrollment
1,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
522
States / cities
Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 372 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 23, 2026, 1:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

High Dose Carfilzomib for Newly Diagnosed Myeloma

NCT02937571
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 23, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

NCT02610777
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Interventions
Azacitidine, Pevonedistat
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2022 · Synced Oct 23, 2026, 1:46 PM EDT
Completed Phase 1 Interventional

A Clinical Safety Study of AT-100 (rhSP-D) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia (BPD)

NCT04662151
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
AT-100, Air-sham
Biological · Procedure
Lead sponsor
Airway Therapeutics, Inc.
Industry
Eligibility
0 Minutes to 96 Hours
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 23, 2026, 1:46 PM EDT
Terminated Phase 3 Interventional

A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant

NCT00005113
View directory record Official record
Conditions
End-Stage Renal Disease, Kidney Transplantation
Interventions
Cyclosporine, Sirolimus, Tacrolimus
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 20 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 23, 2026, 1:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Retrospective Clinical Trial Comparing Radiologists' Diagnosis Accuracy in Lung Cancer Screening Population With and Without the Help of an AI/ML Tech-based SaMD

NCT06751576
View directory record Official record
Conditions
High Risk Cancer, Lung Cancer
Interventions
Median LCS
Device
Lead sponsor
Median Technologies
Industry
Eligibility
50 Years to 80 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Memphis, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 23, 2026, 1:46 PM EDT
Terminated Not applicable Interventional Results available

Mitigation of Postoperative Delirium in High-Risk Patients

NCT05777187
View directory record Official record
Conditions
Post-operative Delirium, Decision Support Systems, Clinical, Cognitive Impairment
Interventions
Clinical Decision Support
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 120 Years
Enrollment
7,412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 23, 2026, 1:46 PM EDT
Recruiting Phase 2 Interventional

ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty

NCT06753916
View directory record Official record
Conditions
Corneal Transplant Failure
Interventions
Corneal Donor Tissue with Cross Linking, Corneal Donor Tissue without Cross Linking
Procedure
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
12
States / cities
Irvine, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 23, 2026, 1:46 PM EDT
Completed Phase 2 Interventional

A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

NCT01113957
View directory record Official record
Conditions
Ovarian Cancer
Interventions
ABT-888, pegylated liposomal doxorubicin, temozolomide
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Duarte, California • Encino, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 23, 2026, 1:46 PM EDT
Completed No phase listed Observational

A Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn

NCT03755128
View directory record Official record
Conditions
Early Onset Severe Hemolytic Disease of the Fetus and Newborn (EOS-HDFN), Erythroblastosis, Fetal
Interventions
No intervention
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
New York, New York • Cincinnati, Ohio • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 23, 2026, 1:46 PM EDT
Recruiting No phase listed Observational

Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE

NCT07594392
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Coronary Artery Calcium Scan, Carotid Artery Ultrasound, Lipoprotein(a) Measurement, Vascular Function Testing
Diagnostic Test
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 1:46 PM EDT
Completed Not applicable Interventional

Reducing Disparities in Primary Prevention of Cardiovascular Disease

NCT01610609
View directory record Official record
Conditions
Cardiovascular Diseases, Cholesterol, LDL
Interventions
Population Health Management Intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
35 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Flagstaff, Arizona • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 23, 2026, 1:46 PM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577
View directory record Official record
Conditions
Melanoma
Interventions
Intismeran autogene, Pembrolizumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,089 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
34
States / cities
Springdale, Arkansas • Los Angeles, California • San Francisco, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 23, 2026, 1:46 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

NCT05733715
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Pembrolizumab infusion, Lenvatinib tablet
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 23, 2026, 1:46 PM EDT
Not listed Phase 1 Interventional

Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients

NCT05195125
View directory record Official record
Conditions
End Stage Liver DIsease, Obesity, Acute Kidney Injury
Interventions
Direct Peritoneal Resuscitation
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 23, 2026, 1:46 PM EDT
Completed Phase 2 Interventional

RECOVER I Impella RECOVER LP/LD 5.0 Support System Safety and Feasibility Study

NCT00596726
View directory record Official record
Conditions
Cardiac Surgery
Interventions
IMPELLA LP/LD 5.0
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
7
States / cities
Baltimore, Maryland • Boston, Massachusetts • New Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated May 27, 2010 · Synced Oct 23, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)

NCT01313507
View directory record Official record
Conditions
Primary Immunodeficiency Disease
Interventions
NewGam
Biological
Lead sponsor
Octapharma
Industry
Eligibility
2 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Irvine, California • Centennial, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 23, 2026, 1:46 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Evacetrapib in High-Risk Vascular Disease

NCT01687998
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Evacetrapib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
12,092 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 173 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 23, 2026, 1:46 PM EDT
Completed Not applicable Interventional Results available

HIRREM Hot Flashes Study

NCT03512002
View directory record Official record
Conditions
Vasomotor Symptoms, Hot Flashes, Menopause
Interventions
HIRREM, Continued Current Care
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 23, 2026, 1:46 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

NCT04008030
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Ipilimumab, Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Bevacizumab, Cetuximab, Nivolumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 23, 2026, 1:46 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

NCT03674411
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI), Tacrolimus (Tac), Mycophenolate Mofetil (MMF), Granulocyte Colony-Stimulating Factor (G-CSF), Busulfan (BU), Melphalan, MGTA 456 Infusion
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 23, 2026, 1:46 PM EDT
Completed Not applicable Interventional

Neurofeedback Training for High Risk Psychosis

NCT03447548
View directory record Official record
Conditions
Prodromal Schizophrenia
Interventions
Neurofeedback processing speed training, Active control
Behavioral
Lead sponsor
Hartford Hospital
Other
Eligibility
12 Years to 25 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 23, 2026, 1:46 PM EDT